The purpose of this study is to characterize tumour uptake of somatostatin analog
68Ga-DOTATOC in patients with either primary or recurrent malignant glioma. The investigators
hypothesis is that some primary and recurrent malignant gliomas overexpress SST2 receptor
which can be imaged with 68Ga-DOTATOC PET/CT. The investigators also hypothesize that tumor
uptake of 68Ga-DOTATOC correlates with immunohistochemically determined SST2 receptor status
of the tumor specimen.